
ARHGAP32 Expression in Different Cancer Types
BRCA
HNSC
COAD
LUAD
STAD
LUSC
BLCA
PRAD
ESCA
CESC
KIRC
SKCM
LGG
READ
OV
PAAD
UCEC
THCA
LIHC
GBM
KIRP
SARC
MESO
KICH
PCPG
TGCT
THYM
UCS
ACC
CHOL
UVM
LAML
Cancer Type
0
200
400
Number of Cases


Cryptic STMN2 Expression in Different Cancer Types
BRCA
STAD
HNSC
COAD
ESCA
LUSC
BLCA
LUAD
CESC
READ
PAAD
PRAD
OV
SKCM
UCEC
LGG
GBM
KIRC
KIRP
LIHC
MESO
THCA
ACC
SARC
TGCT
UCS
Cancer Type
0
100
200
300
Number of Cases


Cryptic ARHGAP32 Expression in Different Cancer Sites
Primary Site of Cancer
Breast
Colorectal
Stomach
Head and Neck
Lung
Esophagus
Bladder
Cervix
Pancreas
Prostate
Ovary
Brain
Skin
Uterus
Kidney
Liver
Pleura
Thyroid
Adrenal Gland
Soft Tissue
Testis
0
100
200
300
Number of Cases


Average STMN2 Junction Coverage in Different Cancer Sites
Primary Site of Cancer
Liver
Stomach
Esophagus
Ovary
Soft Tissue
Skin
Head and Neck
Breast
Cervix
Lung
Thyroid
Pleura
Adrenal Gland
Testis
Bladder
Kidney
Brain
Pancreas
Colorectal
Prostate
Uterus
25
50
75
100
125
Junction Average Coverage


ARHGAP32 Cryptic Coverage in Different Cancer Sites
Primary Site of Cancer
Adrenal Gland
Uterus
Colorectal
Bladder
Prostate
Cervix
Lung
Pancreas
Breast
Thyroid
Pleura
Head and Neck
Brain
Kidney
Skin
Testis
Soft Tissue
Liver
Stomach
Esophagus
Ovary
−1.0
−0.5
0.0
0.5
1.0
Log10 Reads per Million


Adrenal Gland
Uterus
Thyroid
Stomach
Prostate
Esophagus
Cervix
Breast
Bladder
Skin
Lung
Testis
Soft Tissue
Pleura
Pancreas
Ovary
Liver
Kidney
Head and Neck
Colorectal
Brain
Primary Site of Cancer
10
20
ARHGAP32 Cryptic Coverage


Fraction of all cryptic ARHGAP32 cases that are of each cancer type
BRCA
STAD
HNSC
COAD
ESCA
LUSC
BLCA
LUAD
CESC
READ
PAAD
PRAD
OV
SKCM
UCEC
LGG
GBM
THCA
MESO
LIHC
KIRP
KIRC
UCS
TGCT
SARC
ACC
Cancer Type
0%
5%
10%
15%
20%
Percentage of Cases


Fraction of all cryptic ARHGAP32 cases that are in each cancer site
Primary Sites of Cancer
Breast
Colorectal
Stomach
Head and Neck
Lung
Esophagus
Bladder
Cervix
Pancreas
Prostate
Ovary
Brain
Skin
Uterus
Kidney
Thyroid
Pleura
Liver
Testis
Soft Tissue
Adrenal Gland
0%
5%
10%
15%
20%
Percentage of Cases


SKCM
LUSC
LUAD
BLCA
STAD
ESCA
HNSC
COAD
LIHC
CESC
READ
OV
KIRP
ACC
KIRC
UCS
UCEC
BRCA
GBM
PAAD
SARC
TGCT
MESO
LGG
PRAD
THCA
Cancer Type
N.S.
***
0
500
1000
1500
Mutation Count


NS.
600
400
200
0
Mutation Count
3
4
5
6
7
8
9
10
11
12
14
16
19
27
Number of ARHGAP32 cryptic events


Mutation Count
Number of ARHGAP32 cryptic events
10
20
count
16
12
8
4


Percentage of Cases with Cryptic ARHGAP32 Events
Percentage of Cases
6 000%
4 000%
2 000%
0%
KIRC
SARC
THCA
LIHC
TGCT
KIRP
GBM
ACC
LGG
UCEC
UCS
OV
SKCM
MESO
PRAD
LUAD
PAAD
LUSC
BLCA
CESC
BRCA
HNSC
COAD
STAD
ESCA
Cancer Type


blca
brca
cesc
oadrea
esca
gbm
hnsc
kirc
kirp
lgg
lihc
luad
lusc
meso
ov
paad
pcpg
prad
sarc
skcm
stad
thca
ucec
ucs
Log10 Mutation Count
FALSE
TRUE
Cancer Type
Cryptic ARHGAP32 detected
FALSE
TR


Kaplan–Meier Curve: ARHGAP32 Cryptic Events
Overall Survival Probability
1.0
0.8
0.6
0.4
0
100
200
Months


Kaplan–Meier Curve: No ARHGAP32 Cryptic Events
Overall Survival Probability
1.00
0.75
0.50
0.25
0.00
0
100
200
300
Months



Number at risk

FALSE	1635	69	12	1
TRUE	1287	46	5	0


density
0.02
0.01
0.00
0
100
200
300
Survival months with disease
arhgap32_cryptic_detected
FALSE
TRUE


blca
brca
cesc
oadrea
esca
0.97
0.057
0.17
0.45
0.83
gbm
hnsc
kirc
kirp
lgg
0.82
0.11
0.79
0.74
0.2
lihc
luad
lusc
meso
ov
0.75
0.63
0.95
0.39
1
paad
pcpg
prad
sarc
skcm
0.4
0.87
0.078
0.72
0.97
stad
thca
ucec
ucs
0.14
0.32
0.88
0.7
FALSE
TRUE
Aneuploidy Score
Cancer Type
Cryptic ARHGAP32 detected
FALSE
T